Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
Press releases 2024/03/28
Your specialized CDMO for viral, bacterial, therapeutic, and conjugate vaccines
From discovery to phase II clinical trial.
Even the most promising vaccines can fail in the transition from laboratory to large-scale production. At Intravacc, we understand the challenges of vaccine development and offer strategies to help you successfully reduce risks and costs. How? By giving you access to our knowledgeable and experienced team, our proprietary vaccine production platforms, and our vaccine pipeline.
Intravacc at a glance
100+
Highly Qualified employees.
50+
Customers worldwide.
300+
Scientific publications.
2000+
State-of-the-art facilities.
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
Press releases 2024/03/26
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
Press releases 2024/01/11
The magic is in the knowledge
Make your vaccine idea reality with less risk and at lower cost. See how our know-how and expertise can streamline your development program.
Success stories
Highlights of our milestones, the accomplishments of our team, and the successes of our partners.
A unique pipeline of vaccine candidates open for licensing.
Our partners
